Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

What happened

Arrowhead Pharmaceuticals said it will present data at the American Heart Association Scientific Sessions in Chicago. The listed oral presentations cover an early human trial of a drug designed to lower PCSK9 and APOC3, and pooled results on plozasiran, triglycerides, and acute pancreatitis risk.

Confirmed

Global impact / market context

The presentations address treatments for abnormal blood fats, including triglycerides, which are a type of fat in the blood. If the data support meaningful benefits, they could strengthen the case for further development and eventually affect treatment options and Arrowhead’s research spending; the article gives no results.

Analyst inference

The announcement provides conference topics and scheduled presentations, not clinical findings, trial outcomes, or financial forecasts. Investors therefore have no reported efficacy or safety results here to assess, and any effect on future revenue, development costs, or company value remains uncertain.

Analyst inference

What to watch

1. Review the presented results for the dual-target RNAi trial, which aims to silence PCSK9 and APOC3; the article identifies the study but reports no findings. Analyst inference
2. Look for the pooled SHASTA-3 and SHASTA-4 analysis results on plozasiran, triglyceride reduction, and acute pancreatitis risk in severe hypertriglyceridemia. Analyst inference
3. Check whether later company updates describe next development steps, safety, or additional study needs; such decisions could change research costs and the timing of potential commercial revenue. Analyst inference

Evidence

• Original source link unavailable